Clinical trials · Pennsylvania
Atopic Dermatitis clinical trials in Pennsylvania
We’re tracking 19 recruiting atopic dermatitis studies with a site in Pennsylvania — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07003425RecruitingPhase 2
Long-term safety and effectiveness of APG777 for eczema
This study looks at the long-term safety and how well APG777 works for people with eczema (atopic dermatitis). It is for people who have already completed treatment with APG777 in an earlier study and may benefit from continuing it.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07223697RecruitingPhase 2
Long-term safety of Afimkibart for eczema patients
This study tests the long-term safety and effectiveness of a medicine called Afimkibart for people with atopic dermatitis (eczema). It is for people who already completed a previous study of this medicine and had at least a 50% improvement in their eczema.
Camp Hill, PennsylvaniaAges 18 years+ - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Camp Hill, PennsylvaniaAges 18–75 - NCT05995964RecruitingPhase 2
Study of two new medicines for eczema
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06055361RecruitingPhase 1
Studying a new injection for moderate to severe eczema
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
Camp Hill, PennsylvaniaAges 18 years+ - NCT07277660RecruitingPhase 2
Study of galvokimig for adults with moderate-to-severe eczema
This trial tests whether a new medication, galvokimig, can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with creams or ointments. The study will measure how well the drug works, its safety, and how it behaves in your body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06928246RecruitingPhase 1
Botox for Eczema: A Skin & Nerve Study
This trial tests whether Botox injections can improve eczema by calming nerve-immune system interactions. It is for adults with mild-to-moderate eczema who have not used certain stronger treatments recently.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Camp Hill, PennsylvaniaAges 18–65 - NCT06464133Enrolling by invitation
Filaggrin gene study in Latinx patients with eczema
This study looks for gene changes (filaggrin mutations) in Latinx/Hispanic patients with atopic dermatitis (eczema) to better understand how these genes affect the condition. It involves a simple skin test or saliva sample.
Philadelphia, PennsylvaniaAges Any age - NCT05492578Enrolling by invitationPhase 2/Phase 3
Long-term follow-up of amlitelimab for moderate to severe eczema
This trial studies the long-term safety and effectiveness of amlitelimab in people with moderate to severe atopic dermatitis (eczema). You may be eligible if you previously joined an amlitelimab eczema study and are continuing into a longer follow-up phase.
Philadelphia, PennsylvaniaAges 12 years+ - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Philadelphia, PennsylvaniaAges 18–65 - NCT06988605Recruiting
Nemolizumab for teens and adults with moderate-to-severe eczema
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
Philadelphia, PennsylvaniaAges 12 years+ - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Plymouth Meeting, PennsylvaniaAges 18–63 - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Pittsburgh, PennsylvaniaAges 12 years+ - NCT00177268Recruiting
Collecting blood and tissue samples in skin diseases research
This study collects blood, urine, and possibly small tissue samples to learn more about cutaneous T-cell lymphoma (CTCL) and either eczema or atopic dermatitis. It may help researchers better understand these skin conditions and improve future treatments.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07216027RecruitingPhase 2
A study of a new eczema medicine for adults
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
Pittsburgh, PennsylvaniaAges 18–64 - NCT07748169Recruiting
Observational study of skin disease patients
This study looks at the health records of people with skin diseases to learn more about their care and outcomes. It may help improve future treatments.
Philadelphia, PennsylvaniaAges Any age - NCT06564389RecruitingPhase 1
First-in-human study of PF-07832837 in healthy adults and eczema patients
This trial is testing a new investigational medicine (PF-07832837) for safety in healthy adults and in people with moderate to severe atopic dermatitis (eczema). It is a first-in-human study, so it looks at how well the body tolerates the medicine.
Philadelphia, PennsylvaniaAges 18–70 - NCT06241118RecruitingPhase 3
New injection for eczema not helped by other advanced treatments
This study tests a new injection called amlitelimab for teens and adults with moderate-to-severe eczema that hasn't gotten better with other advanced treatments like biologics or JAK inhibitor pills. It's given along with steroid creams to see if it can improve symptoms.
Philadelphia, PennsylvaniaAges 12 years+
Atopic Dermatitis trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting atopic dermatitis studies listed above.
- Paddington Testing Company · 4 studies
- Best Skin Research · 3 studies
- Clinical Research of Philadelphia · 3 studies
- University of Pennsylvania · 3 studies
- University of Pittsburgh Medical Center · 3 studies
- UPMC Department of Dermatology · 3 studies
- Dermatology Associates of Plymouth Meeting · 2 studies
- Atd002 52019
What taking part in a atopic dermatitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Atopic Dermatitis trials in other states
Common questions
- Are there atopic dermatitis clinical trials in Pennsylvania?
- Yes. We're currently tracking 19 recruiting atopic dermatitis studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a atopic dermatitis study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New atopic dermatitis studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.